{"public_id":"cl_1f0a9cab908893de077616b29f7eb998","status":"active","superseded_by_public_id":null,"corpus_id":235126882,"text":"Higher R&D investments are associated with higher R&D output.","confidence":0.96,"paper":{"corpus_id":235126882,"title":"R&D efficiency of leading pharmaceutical companies - a 20-year analysis.","url":"https://sah.borca.ai/papers/235126882"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.96,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_5c6abaaf35bfba462b566a896f6fecf8","name":"R&D output","description":"The measurable results of research and development activity.","types":["output"],"url":"https://sah.borca.ai/concepts/co_5c6abaaf35bfba462b566a896f6fecf8"},{"public_id":"co_b3c8c329fe72079c7265ed980fabaecb","name":"R&D investments","description":"Resources allocated to research and development activities.","types":["input"],"url":"https://sah.borca.ai/concepts/co_b3c8c329fe72079c7265ed980fabaecb"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_1f0a9cab908893de077616b29f7eb998"}